%0 Journal Article
%T Ofatumumab ¨C a valid treatment option for chronic lymphocytic leukemia patients
%A Salma M AlDallal
%J Archive of "Therapeutics and Clinical Risk Management".
%D 2017
%R 10.2147/TCRM.S140023
%X Ofatumumab Arzerra£¿ is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody¡¯s therapeutic effect on chronic lymphocytic leukemia
%K ofatumumab
%K cell-mediated cytotoxicity
%K chronic lymphocytic leukemia
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530057/